These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 8988341)

  • 41. Anti-resorptive therapies for osteoporosis.
    Reid IR
    Semin Cell Dev Biol; 2008 Oct; 19(5):473-8. PubMed ID: 18760372
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Clinical implications of bisphosphonate for bone metastases of prostate cancer].
    Kitagawa Y; Konaka H; Mizokami A; Namiki M
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():356-9. PubMed ID: 18161131
    [No Abstract]   [Full Text] [Related]  

  • 43. Topical bisphosphonate augments fixation of bone-grafted hydroxyapatite coated implants, BMP-2 causes resorption-based decrease in bone.
    Baas J; Vestermark M; Jensen T; Bechtold J; Soballe K; Jakobsen T
    Bone; 2017 Apr; 97():76-82. PubMed ID: 28082076
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Pharmacological profile and clinical efficacy of minodronic acid hydrate as a new therapeutic agent for osteoporosis].
    Tanaka M; Mori H; Shimizu K; Toshiyuki ; Matsuoka ; Yamamotoya H; Minamide T; Mori M; Nozaki K; Usui T; Shimokawa K; Suzuki H; Aoyama K; Kimoto A; Sasamata M; Miyata K
    Nihon Yakurigaku Zasshi; 2009 Sep; 134(3):149-57. PubMed ID: 19749488
    [No Abstract]   [Full Text] [Related]  

  • 45. [Efficacy and safety of long-term treatment with bisphosphonate for osteoporosis in Japanese].
    Kushida K
    Nihon Rinsho; 2004 Feb; 62 Suppl 2():455-60. PubMed ID: 15035170
    [No Abstract]   [Full Text] [Related]  

  • 46. Interaction between effects of parathyroid hormone and bisphosphonate on regulation of osteoclast activity by the osteoblast-like cell line UMR-106.
    Yu X; Schøller J; Foged NT
    Bone; 1996 Oct; 19(4):339-45. PubMed ID: 8894139
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effects of the bisphosphonate tiludronate on bone resorption, calcium balance, and bone mineral density.
    Ammann P; Rizzoli R; Caverzasio J; Shigematsu T; Slosman D; Bonjour JP
    J Bone Miner Res; 1993 Dec; 8(12):1491-8. PubMed ID: 8304051
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Bisphosphonates for osteoporosis--where do we go from here?
    Whitaker M; Guo J; Kehoe T; Benson G
    N Engl J Med; 2012 May; 366(22):2048-51. PubMed ID: 22571168
    [No Abstract]   [Full Text] [Related]  

  • 49. [Pharmacology of bone resorption inhibitor].
    Menuki K; Sakai A
    Nihon Rinsho; 2015 Oct; 73(10):1634-8. PubMed ID: 26529923
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [[Antiresorptive agents in the treatment of osteoporosis].
    Novak S
    Reumatizam; 2014; 61(2):89-94. PubMed ID: 25427401
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Strontium ranelate: a novel mode of action optimizing bone formation and resorption.
    Marie PJ
    Osteoporos Int; 2005 Jan; 16 Suppl 1():S7-10. PubMed ID: 15578159
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The effects of bisphosphonates on the resorption cycle of isolated osteoclasts.
    Selander K; Lehenkari P; Väänänen HK
    Calcif Tissue Int; 1994 Nov; 55(5):368-75. PubMed ID: 7532540
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The relative merits of anabolics versus anti-resorptive compounds: where our targets should be, and whether we are addressing them.
    Gasser JA
    Curr Opin Pharmacol; 2006 Jun; 6(3):313-8. PubMed ID: 16650802
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Bisphosphonates: pharmacology and effects on the growing skeleton.
    Papapoulos SE
    Acta Univ Carol Med (Praha); 1994; 40(1-4):29-32. PubMed ID: 9355668
    [No Abstract]   [Full Text] [Related]  

  • 55. Zoledronate prevents lactation induced bone loss and results in additional post-lactation bone mass in mice.
    Wendelboe MH; Thomsen JS; Henriksen K; Vegger JB; Brüel A
    Bone; 2016 Jun; 87():27-36. PubMed ID: 27021151
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effects of tiludronate on bone mass, structure, and turnover at the epiphyseal, primary, and secondary spongiosa in the proximal tibia of growing rats after sciatic neurectomy.
    Murakami H; Nakamura T; Tsurukami H; Abe M; Barbier A; Suzuki K
    J Bone Miner Res; 1994 Sep; 9(9):1355-64. PubMed ID: 7529459
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pamidronate prevents bone loss associated with carrageenan arthritis by reducing resorptive activity but not recruitment of osteoclasts.
    Moran EL; Fornasier TL; Bogoch TR
    J Orthop Res; 2000 Nov; 18(6):873-81. PubMed ID: 11192246
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Bisphosphonate therapy for secondary osteoporosis: adult perspective.
    Reid IR
    Horm Res Paediatr; 2011; 76 Suppl 1():28-32. PubMed ID: 21778745
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The importance of growth hormone (GH) and GH secretagogues for bone mass and density.
    Svensson J
    Curr Pharm Des; 2002; 8(23):2023-32. PubMed ID: 12171516
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Glucocorticoid-induced osteoporosis: an update.
    Mazziotti G; Angeli A; Bilezikian JP; Canalis E; Giustina A
    Trends Endocrinol Metab; 2006; 17(4):144-9. PubMed ID: 16678739
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.